𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Profile: GSK-3 inhibitors: potential drugs for neurodegenerative disorders

✍ Scribed by David Gurwitz; Hagit Eldar-Finkelman

Book ID
114383732
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
86 KB
Volume
6
Category
Article
ISSN
1359-6446

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Glycogen synthase kinase 3 (GSK-3) inhib
Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
✍ Ana Martinez; Ana Castro; Isabel Dorronsoro; Mercedes Alonso πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 135 KB

Glycogen synthase kinase 3 (GSK-3) was initially described as a key enzyme involved in glycogen metabolism, but is now known to regulate a diverse array of cell functions. Two forms of the enzyme, GSK-3alpha and GSK-3beta, have been previously identified. Small molecules inhibitors of GSK-3 may, the

GSK-3 is a viable potential target for t
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder
✍ Michael K. Rowe; Charlotte Wiest; De-Maw Chuang πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 248 KB

Bipolar disorder is a serious psychiatric condition that has been treated for over 50 years with lithium. Lithium is a well established glycogen synthase kinase-3 (GSK-3) inhibitor, suggesting that manipulating GSK-3 may have therapeutic value in treating bipolar disorder. GSK-3 is regulated by a wi